$0.7198
0.0188[2.68%]
Last update: 8:34AM Get Real Time Here
Spruce Biosciences
(NASDAQ:SPRB)Spruce Biosciences Stock (NASDAQ:SPRB), Analyst Ratings, Price Targets, Predictions
Spruce Biosciences Inc has a consensus price target of $3.09, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, JMP Securities, and HC Wainwright & Co. on March 14, 2024. With an average price target of $1.67 between RBC Capital, JMP Securities, and HC Wainwright & Co., there's an implied 131.55% upside for Spruce Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
JMP Securities
HC Wainwright & Co.
Leerink Partners
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Spruce Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 177.85% | RBC Capital | Gregory Renza | $9 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 316.78% | JMP Securities | Jonathan Wolleben | $8 → $3 | Maintains | Market Outperform | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 177.85% | Leerink Partners | Joseph Schwartz | $9 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | — | Ladenburg Thalmann | Aydin Huseynov | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | — | Guggenheim | Evan Wang | — | Downgrade | Buy → Neutral | Get Alert |
| 03/05/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1150.35% | RBC Capital | Gregory Renza | → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1150.35% | RBC Capital | Gregory Renza | $8 → $9 | Maintains | Outperform | Get Alert |
| 02/21/2024 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1289.27% | Guggenheim | Evan Wang | → $10 | Initiates | → Buy | Get Alert |
| 11/20/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1289.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1011.42% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1289.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1150.35% | SVB Leerink | Joseph Schwartz | $3 → $9 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/18/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 872.49% | Oppenheimer | Hartaj Singh | $8 → $7 | Maintains | Outperform | Get Alert |
| 08/18/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1289.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1011.42% | JMP Securities | Jonathan Wolleben | $7 → $8 | Maintains | Outperform | Get Alert |
| 08/15/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1011.42% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 06/13/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1289.27% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | SPRB | Buy Now | Spruce Biosciences | $0.72 | 1011.42% | Oppenheimer | Hartaj Singh | → $8 | Reiterates | Outperform → Outperform | Get Alert |
FAQ
What is the target price for Spruce Biosciences (SPRB)?
The latest price target for Spruce Biosciences (NASDAQ: SPRB) was reported by RBC Capital on March 14, 2024. The analyst firm set a price target for $2.00 expecting SPRB to rise to within 12 months (a possible 177.85% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spruce Biosciences (SPRB)?
The latest analyst rating for Spruce Biosciences (NASDAQ: SPRB) was provided by RBC Capital, and Spruce Biosciences downgraded their sector perform rating.
When was the last upgrade for Spruce Biosciences (SPRB)?
The last upgrade for Spruce Biosciences Inc happened on September 8, 2023 when SVB Leerink raised their price target to $9. SVB Leerink previously had a market perform for Spruce Biosciences Inc.
When was the last downgrade for Spruce Biosciences (SPRB)?
The last downgrade for Spruce Biosciences Inc happened on March 14, 2024 when RBC Capital changed their price target from $9 to $2 for Spruce Biosciences Inc.
When is the next analyst rating going to be posted or updated for Spruce Biosciences (SPRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
Is the Analyst Rating Spruce Biosciences (SPRB) correct?
While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a downgraded with a price target of $9.00 to $2.00. The current price Spruce Biosciences (SPRB) is trading at is $0.72, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.